- 690studies on this subject, of 27,380 in the library
- 661peer-reviewed
- 1979–2026years published
- 45median usefulness score out of 100
These counts and lists are worked out from the library itself each time the page loads. A score rates how much weight a study can bear — its design, journal, evidence and recency — not whether its result is good news. How we score a study. For a plain-English guide to this subject, see Blood tests & biomarkers.
The 20 highest-scoring studies
- Brain MRI signatures across sex and CSF Alzheimer's disease biomarkers
- CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab
-
Sex Differences in Apolipoprotein E and Alzheimer Disease Pathology Across Ancestries
This meta-analysis examined how the APOE gene, sex and ancestry relate to three core CSF Alzheimer's biomarkers. It is about understanding risk and biomarker patterns across groups, not about treating or preventing Alzheimer's.
- A phase II trial of tideglusib in Alzheimer's disease
- Associations between sleep disturbance and cerebrospinal fluid Aβ, and shared proteomic signatures in Alzheimer's disease
- Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta
- Epigenetic Age and Resilience in the Framingham Heart Study
- Midlife and Late-Life Alzheimer Disease Blood Biomarkers and 11-Year Cognitive Decline
- Proteomics reveals three molecular subtypes of Alzheimer's disease with distinct progression patterns
- Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative
- Slowing gait speed precedes cognitive decline by several years
- Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging
- Association of white matter hyperintensities with cognitive decline and neurodegeneration
-
Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers
This cohort study examined whether blood markers of liver function are associated with cognitive dysfunction and with amyloid, tau, and neurodegeneration biomarkers for Alzheimer disease. It reports associations only and does not show that any liver-related treatment, cure, or prevention works.
-
Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity
This study examined the course of medial temporal tau deposition seen on PET in older individuals without amyloid-beta pathology and its link to Alzheimer's disease. It is an observational cohort study and does not test any treatment, cure, or prevention.
-
Core CSF Biomarker Profile in Cerebral Amyloid Angiopathy: Updated Meta-Analysis
This meta-analysis compared five core cerebrospinal fluid biomarkers in people with sporadic cerebral amyloid angiopathy versus controls and/or patients with Alzheimer disease. It is about characterizing biomarkers of cerebral amyloid angiopathy, not about treating, curing or preventing Alzheimer disease.
-
Progression of Subjective Cognitive Decline to MCI or Dementia in Relation to Biomarkers for Alzheimer Disease: A Meta-analysis
This meta-analysis examined whether people with subjective cognitive decline who have Alzheimer's disease biomarkers are more likely to progress to mild cognitive impairment or dementia. It is a review of observational studies and does not test any treatment, cure, or prevention.
- Liver-Specific Polygenic Risk Score Is Associated with Alzheimer's Disease Diagnosis
-
Association of Extracellular Vesicle Biomarkers With Alzheimer Disease in the Baltimore Longitudinal Study of Aging
This case-control study tested whether markers in plasma neuronal-enriched extracellular vesicles could predict Alzheimer disease in cognitively normal participants who later developed it. It is a validation study of a blood-based predictor, not a treatment, cure, or prevention.
-
Relevance of Minor Neuropsychological Deficits in Patients With Subjective Cognitive Decline
In people with subjective cognitive decline, minor deficits on neuropsychological tests were related to Alzheimer's CSF biomarkers and progression to mild cognitive impairment. This may help identify who is at higher risk earlier, but it does not test a treatment or prevention.
See all 690 studies in Tau biomarkers, with filters →
Newest additions on this subject
- CSF Alzheimer’s Disease Biomarkers in Relation to Functional Status and Tofersen Treatment Response in ALS
- A digital biomarker of white-matter routing from diffusion MRI as an early biomarker of Alzheimer’s disease
- Discovery of a brain-penetrant CHI3L1 inhibitor as an oral modulator of neuroinflammation in Alzheimers disease
- Genetic Architecture of Plasma Amyloid and Tau Biomarkers in the Amish
- Evidence for Reduced Somatic T-Cell Receptor Sequence Diversity Profiles Among Midwestern Amish in an Aging Cohort Study
- Cerebrospinal fluid dopa-decarboxylase is a biomarker of dopaminergic dysfunction
- Large-scale cerebrospinal fluid proteomics identifies diagnostic biomarker candidates across the clinico-pathological continuum of frontotemporal lobar degeneration
- Brain-wide Cerebrospinal Fluid Recirculation Collapse in Alzheimer’s Disease
- Integrating CSF and EV Proteomes Enhances Biomarker Discovery by Capturing Shared Variation Across Compartments
- Clinical Factors Associated With Discordant Plasma P-Tau217 and Established Alzheimer Disease Biomarkers
All 690 studies in Tau biomarkers, newest first →
What the library holds on this subject
By review status
| Status | Studies |
|---|---|
| Peer-reviewed | 661 |
| Preprint — not yet peer-reviewed | 29 |
By strength of evidence
| Rated in our summary | Studies |
|---|---|
| low | 468 |
| moderate | 194 |
| high | 21 |
| not rated | 7 |
Most frequent journals
| Journal | Studies |
|---|---|
| Neurology | 65 |
| Journal of Alzheimer's disease : JAD | 45 |
| Alzheimer's & dementia : the journal of the Alzheimer's Association | 31 |
| Neurobiology of aging | 19 |
| Alzheimer's research & therapy | 18 |
| Alzheimer s & Dementia | 16 |
| Archives of neurology | 14 |
| JAMA neurology | 14 |
| Alzheimer disease and associated disorders | 13 |
| Alzheimer's & dementia (Amsterdam, Netherlands) | 13 |
Studies by year published
| Year | Studies | Bar |
|---|---|---|
| 2026 | 70 | |
| 2025 | 72 | |
| 2024 | 42 | |
| 2023 | 28 | |
| 2022 | 45 | |
| 2021 | 35 | |
| 2020 | 46 | |
| 2019 | 38 | |
| 2018 | 25 | |
| 2017 | 38 | |
| 2016 | 18 | |
| 2015 | 26 | |
| 2014 | 18 | |
| 2013 | 24 | |
| 2012 | 19 | |
| 2011 | 19 | |
| 2010 | 22 | |
| 2009 | 19 | |
| 2008 | 11 | |
| 2007 | 7 | |
| 2006 | 7 | |
| 2005 | 9 | |
| 2004 | 6 | |
| 2003 | 9 | |
| 2002 | 7 | |
| 2001 | 2 | |
| 2000 | 3 | |
| 1999 | 1 | |
| 1998 | 4 | |
| 1996 | 1 | |
| 1995 | 5 | |
| 1994 | 3 | |
| 1993 | 2 | |
| 1992 | 3 | |
| 1991 | 2 | |
| 1989 | 1 | |
| 1985 | 1 | |
| 1984 | 1 | |
| 1979 | 1 |
Counts the 690 studies with a usable publication date. The library is a large sample of published work, not a complete index, so these counts describe the library, not the whole field.
Other subjects in the library
- Getting a diagnosis
- Biomarkers
- Clinical trials
- Prevention and risk
- Caregiving
- How common it is
- Costs and economics
- Genetics
- Laboratory science
- Disease mechanisms
- Vascular contributions
- Prevention trials
- Clinical safety
- Health systems and care delivery
- End-of-life care
- Risk factors
- Digital health tools
- Treatments
- Disparities
- Mild cognitive impairment
- Risk genes beyond APOE
- Brain scans and imaging
- TREM2 and immune genetics
- Cognitive tests and assessment
- Lewy body dementia
- Down syndrome and Alzheimer's
- Long-term cohort studies
- Inflammation and the immune system
- Brain tissue and pathology
- Drug development
- Hippocampus size on brain scans